Monitoring and Dose Adjustment of Eplerenone

Initial Monitoring and Dose Titration

The European Society of Cardiology recommends checking serum potassium and renal function at 1 week and 4 weeks after switching from spironolactone to eplerenone to determine if a dose increase is necessary, with the earliest consideration for dose titration at 4 weeks if potassium remains ≤5.0 mEq/L and renal function is stable 1, 2
Measure serum potassium and creatinine within 2-3 days after initiating eplerenone to detect early hyperkalemia, as this is the highest risk period 2
Recheck serum potassium and creatinine at 1 week after the switch, as this is a critical timepoint mandated by both the FDA label and ESC guidelines 1, 3
Recheck serum potassium and creatinine at 4 weeks to assess tolerance and determine if dose adjustment is appropriate 1, 2, 3

The American Heart Association recommends halving the eplerenone dose if potassium rises to >5.5 mEq/L or creatinine rises to >2.5 mg/dL 1, 2, 3, 4
The European Society of Cardiology recommends stopping eplerenone immediately if potassium ≥6.0 mEq/L or creatinine rises to >3.5 mg/dL 1, 2, 3, 4

The American College of Cardiology recommends not combining eplerenone with both an ACE inhibitor AND an ARB, as this triples hyperkalemia risk 2, 8
The European Society of Cardiology recommends not relying on serum creatinine alone in elderly or low muscle mass patients; calculate eGFR to avoid underestimating renal dysfunction 2, 8
The American Heart Association recommends discontinuing potassium supplements when initiating eplerenone to prevent hyperkalemia 2
The European Society of Cardiology recommends counseling patients to avoid NSAIDs and high-potassium foods, which dramatically increase hyperkalemia risk 2